vexibinol has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, W; Guo, M; Li, H; Liu, D; Wang, Q | 1 |
| Fang, LW; Gu, PY; Huang, WC; Huang, YL; Lin, CF; Liou, CJ | 1 |
2 other study(ies) available for vexibinol and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Sophoraflavanone G suppresses the progression of triple-negative breast cancer via the inactivation of EGFR-PI3K-AKT signaling.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Flavanones; Glomerular Filtration Rate; Humans; Mice; Molecular Docking Simulation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Triple Negative Breast Neoplasms | 2022 |
Sophoraflavanone G from Sophora flavescens induces apoptosis in triple-negative breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Caspases; Cell Line, Tumor; Cell Movement; Cell Survival; Cytochromes c; Female; Flavanones; Humans; MAP Kinase Signaling System; Mitochondria; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sophora; Triple Negative Breast Neoplasms | 2019 |